Charles McWherter
CIK 1588862 · President of R&D · last filed 2025-10-30
Charles McWherter is a President of R&D who has filed 34 SEC Form 4 insider transactions across 2 companies since 2015. The most recent filing, for ETNB, was dated Oct 30, 2025. Across all open-market trades the lifetime net is −$2.1M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
34
-$2.15M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| 89bio, Inc. (ETNB) Delisted | Director | 0 | $14.84 | $0 | $179.8K | 5 | 2025-10-30 |
| CymaBay Therapeutics, Inc. (CBAY) Delisted | President of R&D | 0 | $32.48 | $0 | -$2.33M | 26 | 2024-03-22 |
Recent Filings
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-10-30 | 89bio, Inc. (ETNB) Delisted | Mixed | −25,000 | $0 | EDGAR |
| 2025-02-05 | 89bio, Inc. (ETNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-23 | 89bio, Inc. (ETNB) Delisted | Buy (P) | +15,000 | $99.8K | EDGAR |
| 2024-12-09 | 89bio, Inc. (ETNB) Delisted | Buy (P) | +10,000 | $80.0K | EDGAR |
| 2024-08-07 | 89bio, Inc. (ETNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-22 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Disp (D) | −46,938 | $0 | EDGAR |
| 2024-01-26 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | +31,938 | $0 | EDGAR |
| 2024-01-22 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Mixed | — | -$305.1K | EDGAR |
| 2023-12-18 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Mixed | — | -$186.8K | EDGAR |
| 2023-11-17 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Mixed | — | -$150.6K | EDGAR |